Department of Obstetrics and Gynecology, Kanazawa University, Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8640 Japan.
Anticancer Res. 2011 Jul;31(7):2441-5.
We report on Wilms tumor (WT1) peptide immunotherapy in a patient with intractable ovarian cancer patient over an extended period.
Immunotherapy using WT1 peptide has been undergoing clinical trials for gynecological cancer. We used WT1 peptide vaccination to treat a 53-year-old woman suffering from ovarian cancer with peritoneal dissemination. After 2 months, her pleural and cardiac effusion had disappeared, and the sum of the longest diameter of the target lesion (in the pelvic mass) was reduced. There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). Intradermally administered WT1 peptide vaccination in a case of intractable ovarian cancer stabilized the disease over the course of one year. However, the immunotherapeutic mechanism of WT1 peptide and immunological escape mechanism for carcinoma cells remain to be elucidated.
我们报告了一例在难治性卵巢癌患者中进行的 Wilms 肿瘤（WT1）肽免疫治疗，该患者的治疗时间较长。
WT1 肽免疫疗法已在妇科癌症的临床试验中进行。我们使用 WT1 肽疫苗接种治疗一名 53 岁患有腹膜播散性卵巢癌的女性。2 个月后，她的胸腔和心包积液消失，目标病灶（盆腔肿块）最长直径之和减少。CA125 与单核吞噬细胞/淋巴细胞比值之间存在弱正相关（Spearman's ϱ=0.275，p=0.015）。在一例难治性卵巢癌患者中皮内给予 WT1 肽疫苗接种，使疾病在一年的时间内得到稳定。然而，WT1 肽的免疫治疗机制和癌细胞的免疫逃逸机制仍有待阐明。
